Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

Exelixis Inc

Exelixis Inc. (NASDAQ:EXEL) stock is trading lower on Monday after the company shared detailed results from the STELLAR-303 Phase 3 trial.

The trial evaluated zanzalintinib plus Roche Holdings AG’s (OTC:RHHBY) Tecentriq (atezolizumab) versus Bayer AG’s (OTC:BAYRY) Stivarga (regorafenib) for previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.